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Introduction 
The Royal Society of Tropical Medicine and Hygiene (RSTMH) has a tradition 
of holding joint meetings with fellow European Societies, providing 
opportunities to facilitate discussion, exchange information, foster mutual 
interests and develop collaboration between the societies’ members and 
fellows.  This paper presents the proceedings from a scientific meeting that 
was held between The RSTMH and the Norwegian Infectious Diseases 
Society at Ulleval University Hospital, Oslo on 20th June 2008.  Three 
speakers from each society gave state-of-the-art lectures in their areas of 
expertise and the meeting ended with a series of case presentations.   
 
Tore Godal: “Norway's commitments to maternal and child health” 
Dr Godal, an international public health specialist who has worked with the Bill 
and Melinda Gates Foundation, the World Health Organisation and the Global 
Alliance for Vaccines and Immunisation (GAVI), focussed on progress 
towards achieving the 4th and 5th Millennium Development Goals (MDGs); 
reduction of child mortality and improving maternal health.  Dr Godal 
described the impact of the GAVI programme on childhood mortality: between 
2003-2007 the number of children vaccinated per annum rose from 40 million 
to 170 million, which translated into an estimated rise in lives saved through 
vaccination from 0.7 to 2.9 million. Dr Godal outlined the considerable funding 
that the Norwegian Government has committed, working in partnership with 
other organisations such as the World Bank, towards meeting the MDGs.  The 
MDG strategy was reviewed, noting that goals 4 and 5 are not on target to 
achieve their aims by 2015.  Indeed, in the Africa region the under-5 mortality 
rate is increasing. Least progress has been made in neonatal mortality. Data 
presented at this meeting indicated that there are over 10 million neonatal, 
child and maternal deaths per annum globally. Of these, 0.5 million are 
maternal deaths, there are 2 million neonatal deaths on day 1 of life, 2 million 
neonatal deaths in the first month of life and 1.6 million other children die 
under the age of 5.  2.5 million of these deaths are vaccine preventable. 
There are packages in place to address the causes of mortality such as safe 
delivery, childcare packages, and vaccination campaigns not only to ensure 
currently available vaccines are widely administered but also to develop new 
vaccines against diseases such as rota virus and pneumococcal.  
 
A scheme was described whereby women in Rajasthan, India, were paid 
between $30-50 to deliver in a clinic. The numbers of women who delivered in 
clinic rose from 0.92% in 2004/5 to 76% in 2006/7. This had a major beneficial 
impact on maternal and neonatal mortality. One of the important factors in the 
success of this scheme was the support of senior political leaders.  
 
Gail Davey: “Recent advances in podoconiosis: aetiology and 
consequences” 
Podoconiosis (endemic non-filarial elephantiasis) is a neglected tropical 
disease that affects up to 5% of the population in endemic areas, where it can 
be more prevalent than HIV/AIDS or malaria.  However, the medical and 
scientific communities are often unaware of the existence of the disease 
despite the fact that it is a preventable disease.   
A historical overview was given; podoconiosis may have been described as 
elephantiasis 'of the Arabs' by Rhazes, a Persian physician who taught in 
Baghdad c.905. Over time further references to podoconiosis were made in 
the literature, but it was not until the 1960’s and 1970’s that the disease was 
characterised in more detail through the work of Ernest Price and others 
working in Ethiopia particularly.  He described the natural history and 
distribution of the disease, and started to investigate its aetiology. 
Podoconiosis is a disease of the impoverished.  Development of disease 
requires exposure to a particular type of red clay soil that is volcanic in origin, 
occurs in regions of high seasonal rain fall, high altitude and low income.   
Systematic baseline epidemiological and clinical studies by Dr Davey and her 
colleagues in the Wolaita Zone of southern Ethiopia have provided a firm 
basis for further research on the aetiology and consequences of 
podoconiosis, where most of the recent advances described by Dr Davey 
have occurred.  A programme of research into the genetic basis of the 
disorder in Ethiopia has begun.  Following the observation that cases of 
podoconiosis cluster in families, further studies suggested that it is a heritable 
disease with an autosomal co-dominant gene inheritance.  Work has also 
been undertaken towards defining the biochemical and immunological 
abnormalities underlying the inflammation and fibrosis that lead to pathology.  
In terms of the consequences, research into the economic effects has shown 
that podoconiosis worsens the already dire economic situation of individuals 
who have the disease.  Furthermore, it is a highly stigmatising disease which 
excludes sufferers from religious and social functions and marriage. This 
research is ongoing and a number of collaborators are involved with this 
project both locally and internationally including the Mossy Foot Treatment 
and Prevention Association, a non-governmental organisation based in the 
heart of the Wolaita community.  
 
Eyrun Kjetland: “Treatment of schistosomiasis as an intervention 
against HIV infection in Africa”.   
200 million people in 76 countries have schistosomiasis and 85% of these 
indovodials live on the African continent.  Women may have genital 
schistosomiasis caused by any of the Schistosoma species without symptoms 
in the urinary tract.  It has been estimated that 5-10% of female genital 
schistosomiasis affects the ovaries, 10-30% the fallopian tubes, 1-5% the 
uterus, 60-80% the cervix and 40-60% the vagina.   Schistosomiasis may also 
occur in the external genital region. Dr Kjetland described the typical 
appearances of genital schistosomiasis seen on colposcopy in female 
patients. These include a yellow grainy appearance, contact bleeding and 
neovascularisation. There is much overlap between the geographical 
distribution of schistosomiasis and HIV in sub-Saharan African countries such 
as Zimbabwe where Dr Kjetland is conducting her research.  Groups at 
particular risk of co-infection are those with commuting spouses, those living 
in road side villages or newcomers to the cities.  Genital ulcers caused by 
syphilis and herpes have been hypothesised to increase the transmission of 
HIV.  However, genital schistosomiasis has been overlooked in this context.  
Regression analysis of risk factors for HIV infection has shown an association 
with increasing age, widowhood, infertility and co-infection with type II Herpes 
simplex virus, syphilis and human papilloma virus.  The presence of 
schistosomal ova in cervical smears was also associated with HIV infection.  
The demography of schistosomiasis suggests that schistosomal infection 
precedes HIV infection as it occurs in all age groups including younger 
children who are not sexually active.  In some regions genital schistosomiasis 
is the commonest genital lesion.  It is not clear how the two infections interact 
at a molecular level but there is evidence that schistosomiasis may increase 
the expression of chemokine receptors that are co-receptors for HIV on 
peripheral blood mono-nuclear cells.  
 
Dr Kjetland went on to describe a retrospective and a prospective exploration 
of treatment.  In the retrospective analysis treatment women who had been 
treated early were found to have significantly less contact bleeding and sandy 
patches than women who had been treated after the age of 20 years. 
Furthermore these findings were independent of the current waterbody 
contact. In the prospective analysis women were given a single dose of 
praziquantel and were followed up at 3 months. The two groups (treated and 
untreated) were the given either one more dose or not. A third dose was given 
at 12 months and assessed after 25 months. The results of the latter 
investigation are not conclusive and further, larger studies are required. 
 
Diana Lockwood: “Diagnosing leprosy in a cold climate 1995-2008”  
Dr Lockwood spoke about her experience of leading the major leprosy referral 
centre in the United Kingdom.  In London leprosy is an important imported 
disease and early diagnosis is essential to ensure the best treatment is given 
as soon as possible to prevent permanent consequences such as nerve 
damage.   
A review of the pathology of leprosy was presented describing how the 
polarised immune response correlates with the clinical phenotype, ranging 
from tuberculoid leprosy where there is strong cell mediated immunity and few 
organisms seen on microscopy through borderline leprosy to lepromatous 
leprosy where the immune response is predominantly humoral involving the 
production of antibodies rather than cell mediated immunity and is associated 
with large numbers of bacteria.  
A retrospective review of 180 patients whose leprosy had been diagnosed in 
the UK was presented.  There were three groups of patients; those in whom a 
new diagnosis of leprosy had been made, those who were being referred for 
management of complications or review following treatment and those who 
had been treated previously and were under follow-up.  Data collected 
included the country where leprosy was acquired, when the patient arrived in 
the UK, the time until diagnosis, the clinical type of leprosy and the 
complications experienced by patients. 
 
Over half of the cases came from the Indian subcontinent and approximately 
equal numbers came from Africa, South East Asia and the Americas.  A small 
percentage of cases were born in the UK and cases patients had been 
resident in leprosy endemic areas are between 8-48 years.  Recently 
increasing numbers of Brazilians have been seen with leprosy and this 
reflects changes in migration patterns.  The commonest referral patterns were 
from dermatologists and neurologists but also rheumatologists, orthopaedic 
surgeons, infectious disease clinicians and others referred cases.  
Paradoxically, leprosy appears to be easier to diagnosis in resource-poor 
endemic regions than the UK as significant delays in diagnosis in the UK: the 
median time until diagnosis was approximately 2 years.  Diagnosis was 
delayed because the diagnosis was not recognised by health care 
professionals, or for patient-related reasons, but more commonly delay was 
due to misdiagnosis.  Nerve involvement was common at presentation and 
approximately 1/3 of patients had leprosy reactions.  The main conclusion 
from this talk was to always consider leprosy especially in patients with 
unexplained neuropathy, ulcers and skin lesions.  
  
 
Peter Chiodini: “Challenges in the deployment of new malaria 
diagnostics” 
Rapid diagnostic tests (RDTs) for malaria are antigen detection tests used to 
diagnose the presence of malaria parasites in the blood using a fingerprick 
sample.  Some detect Plasmodium falciparum only, others can detect the 
other species that cause human disease.  They have important potential in 
the management of malaria in countries where malaria is endemic: such 
countries generally lack resources and access to good quality microscopy (the 
conventional tool used for diagnosing malaria) is often lacking.  In this context, 
RDTs are used in settings where the ambient temperatures are high and the 
logistics of delivery of medical supplies to more rural health care facilities may 
be difficult.  The stability of the product and long length of shelf-life are 
important parameters to consider when developing and assessing RDTs.  
Since they are designed for field use they should be simple to use.  Given the 
issues around quality control, the WHO has set target sensitivities for RDTs 
and has a programme for RDT evaluation. 
 
In June 2008 there were 30 manufacturers marketing 88 products which come 
in a variety of forms including dipsticks, cassettes and cards.  There is much 
variation in the performance of RDTs but both between products and between 
locations where they are being used.  A number of other factors can also 
influence the test result including the condition of the devices, the quality of 
their technique and test interpretation.  Professor Chiodini highlighted a few of 
these in more detail.  Concerns have been raised about the conditions that 
RDTs are stored in, in countries where malaria is endemic. Thus, for most the 
recommended storage temperature is between 4-30ºC and most the majority 
of RDTs have a recommended shelf life of up 18 to 24 months, reflecting the 
fact that these tests have been developed and tested in temperate climates. 
However, the ambient temperature is often higher than 30ºC in many malaria 
endemic countries and this leads to concerns about the viability of these tests 
in such conditions.  
The parasite under detection also has an influence on the performance of the 
test.  In addition to the different species, different tests detect structurally 
different antigens and the antigen may persist after treatment in some cases.   
RDTs are being used more frequently in the UK as well and appear to be 
replacing microscopy out of normal working hours in units where experience 
is limited. 
In conclusion, these tests have the potential to transform the diagnosis of 
malaria in the tropics, but meticulous quality control is paramount.  
 
Gunnar Bjune: “The importance of diagnostic delay in tuberculosis 
control” 
Dr Bjune began with an overview of the changing epidemiology of 
tuberculosis (TB), describing how the incidence of the disease fell until the 
early 1980's but since then there has been a global increase in the number of 
cases of TB.  The epidemiology varies between high income and low income 
regions of the world and in high income countries the increase in TB is 
associated with immigration, urbanisation and an increasing marginalised 
society. There was also a lack of recognition of TB in such groups who access 
health care facilities infrequently. Treatment is often sub-optimal in these 
groups for a number of different reasons.  In low income countries HIV co-
infection plays a major role but TB is also associated with increased life 
expectancy, urbanisation, malnutrition and break down of health services.  A 
surprising example of the lack of impact of "the classical" social risk factors is 
the increasing prevalence of TB in north-west Russia since the fall of the 
Soviet Union.  Here the whole increase could in fact be explained by the 
introduction of "emerging successful stains" of Mycobacterium tuberculosis in 
to the area. In particular, the prisons had functioned as breeding sites for this 
expansion since 1992.  In one prison in Archangels, Russia, large clusters of 
cases caused by the Beijing strain of M. tuberculosis were noted.  It was 
evident that most of these strains were acquiring drug resistance without 
losing fitness. A consortium named "TB in the 21st Century" came together to 
investigate this further.  
Studies to date indicate that the Beijing strain is not responsible for the 
epidemic of TB in sub-Saharan Africa but plays a dominant role in South East 
Asia. These observations have led to the finding that, in experimental mice, 
the Beijing strain had lost the ability to develop stable latent TB.  There is also 
increasing evidence that the BCG vaccine does not protect against the Beijing 
strain.  A discussion of the evolution of M. tuberculosis focussed on the fact 
that it is causes chronic infection associated with latency and there are a 
number of selective forces at play including antibiotic treatment and BCG.  M. 
tuberculosis has evolved through loss of genetic material and has acquired a 
number of mechanisms to escape host resistance.  
Meanwhile, efforts are required to control the epidemic through preventing 
transmission.  One of the barriers to this is the number of pulmonary TB cases 
slowly fighting their way toward a correct diagnosis.  These patients are 
contributing the bulk of the infectious reservoir in the community.  However, in 
populations where chronic cough is common and can have many aetiologies, 
how can we rapidly identify the individuals who really do have infectious 
smear positive TB to ensure they get treated more quickly?  Such patients 
often have contact with health facilities at a relatively early stage in their 
history: a simple rapid diagnostic tool that identified the "true TB suspected 
cases" would be a major advance in TB control. 
 
David Molyneux: “From donation to elimination: the Global Filariasis 
Programme ten years on” 
Filariasis is endemic in 83 countries, there are 1.3 billion people at risk and 
120 million people live with the disease.  It is a leading cause of global 
disability, possibly second only to mental health disorders.  There is stigma 
attached to the disease and social and economic consequences which impact 
on the affected individuals’ access education and also marriage prospects.  
Filariasis has been recognised as one of six potentially eradicable infectious 
diseases by the International Task Force for Disease Eradication that was set 
up in 1993 to meet this target.  The elimination strategy has involved multiple 
partners; donors, academia, non-governmental development organisations 
(NGDOs) and particularly endemic countries. The strategy has been to 
interrupt transmission through the use of the drugs diethylcarbamazine and 
albendazole in areas where onchocerciasis is not endemic and albendazole 
and ivermectin where there is onchocerciasis. Albendazole and ivermectin 
(Mectizan) are donated by GSK and Merck & Co. inc. respectively. The other 
arm of the programme is to alleviate and prevent disabilities. To date nearly 2 
billion people have been treated within the context of this programme and one 
of the collateral benefits has been the treatment of hookworm, a major cause 
of anaemia globally other intestinal worms, and ectoparasites in areas where 
ivermectin is used. The disease has been mapped using rapid diagnostic 
tests and during the course of the campaign there has been a reduction of 
83% of antigenemia in sentinel villages in Nigeria; a reduction of 83% of 
positive midnight bloods and a 92% reduction in infected mosquitoes.  
Following treatment interventions, monitoring and evaluation has been critical 
to determine when mass drug administration can be stopped.  Several 
countries are now evaluating if transmission has stopped -Egypt, Sri Lanka, 
Zanzibar and several Pacific island nations. 
 
The meeting concluded with case presentations describing unusual 
manifestations of tropical diseases including babesiosis, dengue fever, genital 
schistosomiasis, leishmaniasis, hydatid disease and an outbreak of malaria.  
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